Beta-blockers (BB) have been traditionally associated with improvement in cardiovascular disease outcomes in patients with ischemic cardiomyopathy. Whether they’re still efficacious in the post-reperfusion era is currently debated in the light of recent controversial reports. In-hospital, 6-month and 12-month mortality were studied in the GULF-COAST, a prospective multicenter cohort of acute coronary syndrome (ACS), in relation to BB use: prior to admission, 24-hour post-admission and on discharge in patients with a left ventricular ejection fraction (LVEF) $\geq 40\%$. On admission, 50.9% of the cohort participants had a LVEF $\geq 40\%$, of whom 1203 (55.4%) were on BB whilst 905 (44.6%) were not. Mean age was 60 (13) years old and 66% were males. Prior BB use or its administration in 24 hours decreased in-hospital mortality (OR = 0.25, 95% CI [0.09–0.67]; OR = 0.16, 95% CI [0.08–0.35]; respectively). BB on discharge lowered 1-month mortality (OR = 0.28, 95% CI [0.11–0.72]), but had a neutral effect on mortality, reinfarction and stroke at 6 and 12 months. Results were unchanged after multivariable adjustments and further sensitivity analysis. In this retrospective cohort of ACS, BB improved in-hospital and 1-month mortality in patients with a LVEF $\geq 40\%$ but had a neutral effect on longer-term outcome.

Several trials conducted in the late 1970’s and 1980’s, such as ISIS-1 (First International Study of Infarct Survival) and BHAT (Beta-Blocker Heart Attack Trial), showed that beta blockers (BB) decrease mortality after myocardial infarction (MI). An earlier meta-analysis of studies in which MI patients were treated with BB reported a 25 percent reduction in one-year mortality.

The treatment of ischemic cardiomyopathy has been revolutionized during the past 2 decades with the introduction of new treatment regimens such as dual anti-platelets, statins and most importantly reperfusion therapy. Progressively, the long-term protective role of BB in MI, once vital, is being questioned. A large metanalysis that included over 100 000 MI patients showed that BB reduce mortality in the pre-reperfusion era but failed to report any long-term survival benefit of BB in trials performed in the post-reperfusion era.

There is still convincing evidence that BB use is beneficial on the short-term outcome. A 2013 meta-analysis of randomized trials concluded that early BB therapy in ACS patients reduces in-hospital mortality, re-infarction and arrhythmias. Nevertheless, it is not known how long BB treatment beneficial post-ACS is. In this paper, we report that previous BB therapy and/or BB treatment up to 24 hours after admission is associated with improved in-hospital outcome. However, BB therapy on discharge was associated only with decreased 1-month mortality, with no effect on mortality at 6 and 12 months.
Results

In-hospital outcome. A total of 3980 patients participated in the Gulf COAST cohort. Out of those, 2028 fulfilled the inclusion criteria (LVEF ≥ 40%) and were included in the analysis (see flow chart- Fig. 1). Among those, 1123 (55.4%) of patients were on a BB on admission whilst 905 (44.6%) were not. Mean age was 60 (13) and 66% were males. Table 1 shows the baseline characteristics of the study groups according to BB on admission. Although they were similar in gender and age, patients on BB had more comorbidities. They had a higher prevalence of dyslipidemia, hypertension and MI, which could probably explain the higher prescription of cardioprotective medications such as aspirin, statins and ACE-inhibitors/ARBs. As expected, the heart rate was lower under BB treatment (82.9 vs 86.9 bpm, p < 0.001).

Within the first 24 hours, 1613 (79.5%) patients were on BB whilst 415 (20.5%) were not. The distribution of cardiometabolic parameters and baseline characteristics in those 2 groups was not significantly different from the one done according to prior BB use at admission.

A total of 31 in-hospital deaths occurred, including one death in a patient who was not on BB on admission and died before receiving any within the first 24 hours. Mortality was lower in patients on BB prior to admission or who received it in 24 hours (OR = 0.25 95% CI [0.09–0.67], p = 0.007; OR = 0.16 95% CI [0.08–0.35], p < 0.001; respectively). Results were unchanged after further multivariable adjustments (OR = 0.28 95% CI [0.09–0.82], p = 0.018; OR = 0.18 95% CI [0.08–0.39], p = 0.001; respectively). There was no association between prior BB use or its administration in 24 hours, and in-hospital mortality by the presence of revascularization (p = 0.551; p = 0.381; respectively) or by the type of ACS (p = 0.454; p = 0.842; respectively).

Long-term outcome. 1921 patients with a LVEF ≥ 40% were discharged alive (Fig. 1), the majority of whom were treated with BB (84.9%). As shown in Table 2, there were more males (68% versus 51.9%, p < 0.001) in the BB group. Those patients were more likely to have had STEMI (26.7% vs 17.2%, p = 0.001) and received more cardioprotective drugs at discharge whereas NSTEMI was more prevalent in the non-BB group. There was a non-significant higher use of thrombolysis and PCI in the BB group. However, the severity of lesions was homogenous among patients who underwent PCI.

At 1 month, there were 18 deaths, giving a cumulative mortality of 2.4%. The mortality was lower in the BB group (OR 0.28, 95% CI 0.11–0.72, p = 0.008), and remained so after multivariable analysis (OR 0.25, 95% CI 0.09–0.67, p = 0.006). There was no association between BB on discharge and one-month mortality by the presence of earlier revascularization at the hospital (p = 0.997) or by the type of ACS (p = 0.995).

At 6 and 12 months, the cumulative mortality was 4.8% and 7.2%; respectively. However, the protection conferred by BB was lost. Similarly, there was no significant difference in the 12-month incidence of reinfarction or stroke (Table 3).

Sensitivity analysis. 511 patients with BB prior to admission were propensity-score matched with other 511 patients with no BB. Both groups were well balanced for baseline characteristics expect for dual anti-platelet therapy (DAP) that was more often prescribed in patients on BB (Supplementary Table 1). Previous BB therapy was associated with lower mortality (OR 0.30, 95% CI 0.11–0.84, p = 0.022), which even remained statistically significant after correction for confounding factors (OR 0.31, 95% CI 0.11–0.87, p = 0.027). On discharge, 291 patients with BB were propensity scored to 291 patients without BB. Both groups were also well balanced...
ACS onset resulted in decreased in-hospital mortality. In a recent Brazilian observational study, oral BB use within the first 24 hours of ACS admission decreases in-hospital mortality. Further, BB on discharge conferred cardiovascular protection up to one month, but no additional benefit on 6 and 12-month mortality, re-infarction and stroke was observed. We showed in this retrospective cohort of ACS that a previous BB therapy or a BB treatment within 24 hours of admission–defined as an BB intake ≤ 24 hours post-admission– decreases in-hospital mortality. However, 6-month and 12-month mortality were not affected by BB prescription at discharge (OR = 0.61; respectively); neither re-infarction or stroke (OR = 0.95, 95% CI 0.35–2.58, p = 0.61; respectively) was observed.

Table 1. Baseline characteristics of patients admitted for ACS at the GULF-COAST, with a LVEF ≤ 40%, according to beta-blockers on admission. Data are shown as number (percentage) or mean ± standard deviation. TIAs = transient ischemic attacks, PAD = peripheral artery disease, CKD = chronic kidney disease, SBP = systolic blood pressure, DBP = diastolic blood pressure, LVEF = Left ventricular ejection fraction, HR = heart rate, ARBs = angiotensin receptor blockers.

| Variable                          | Beta-blockers on admission N=1123 (55.4%) | No beta-blockers on admission N=905 (44.5%) | p value |
|-----------------------------------|------------------------------------------|---------------------------------------------|---------|
| **Past medical history**          |                                          |                                             |         |
| Dyslipidemia                      | 595 (75.4%)                              | 393 (62.0%)                                 | <0.001  |
| Hypertension                      | 692 (87.7%)                              | 500 (78.9%)                                 | <0.001  |
| Diabetes                          | 491 (62.2%)                              | 396 (62.5%)                                 | 0.92    |
| Myocardial infarction             | 290 (36.8%)                              | 88 (13.9%)                                  | <0.001  |
| Stroke/TIAs                       | 66 (8.4%)                                | 50 (7.9%)                                   | 0.46    |
| PAD                               | 25 (3.2%)                                | 15 (2.4%)                                   | 0.36    |
| Cancer                            | 9 (1.1%)                                 | 9 (1.4%)                                    | 0.64    |
| Venous thrombo-embolism           | 3 (0.4%)                                 | 5 (0.8%)                                    | 0.47    |
| CKD                               | 79 (10.0%)                               | 37 (5.8%)                                   | 0.004   |
| **Clinical parameters**           |                                          |                                             |         |
| SBP, mmHg, mean ± SD              | 144.2 ± 28.5                             | 145.0 ± 26.4                                | 0.58    |
| DBP, mmHg, mean ± SD              | 80.0 ± 16.0                              | 82.1 ± 15.7                                 | 0.01    |
| HR, bpm, mean ± SD                | 82.9 ± 20.0                              | 86.9 ± 21.1                                 | <0.001  |
| LVEF, %                           | 53.2 ± 8.3                               | 53.9 ± 8.4                                  | 0.11    |
| **Medications prior to admission**|                                          |                                             |         |
| Aspirin                           | 680 (86.2%)                              | 385 (60.7%)                                 | <0.001  |
| ACE-inhibitors and/or ARBs        | 566 (71.7%)                              | 424 (66.9%)                                 | 0.048   |
| Statins                           | 692 (87.7%)                              | 419 (66.1%)                                 | <0.001  |
| Clopidogrel or prasugrel          | 286 (36.2%)                              | 79 (12.5%)                                  | <0.001  |

Discussion

We showed in this retrospective cohort of ACS that a previous BB therapy or a BB treatment within 24 hours of admission decreases in-hospital mortality. Further, BB on discharge conferred cardiovascular protection up to one month, but no additional benefit on 6 and 12-month mortality, re-infarction or stroke was observed. Early reperfusion has become the cornerstone of ACS treatment. Nevertheless, our results support the hypothesis that BB still have a beneficial role in the post-reperfusion era and improve the outcome in the early course of the disease. Interestingly, patients admitted for ACS under BB therapy in our cohort had a significantly lower mortality although they had more comorbidities. It might be possible that BB protect from fatal events despite the occurrence of ischemia. However, we acknowledge that those patients also received more cardioprotective drugs. Further, the BB group had also a higher prescription of cardiometabolic drugs on discharge. Nevertheless, all those confounding factors were accounted for in the multivariable regression model and the sensitivity analysis, which did not abolish the earlier protective role of BB.

There is no doubt that an early BB therapy in ACS is beneficial on the short-term, even in the post-reperfusion era. A recent analysis of the “International Survey of Acute Coronary Syndromes” showed that an early BB administration–defined as an BB intake ≤ 24 hours post-admission– decreases by almost twice in-hospital mortality. Moreover, BB also improved the left ventricular function, a benefit that was also previously reported with early intravenous metoprolol in ST elevation MI patients included in the METOCARD-CNIC trial. In a meta-analysis that included over 70 000 patients, early intravenous BB therapy during ACS reduced mortality, ventricular tachyarrhythmias and reinfarction. In a recent Brazilian observational study, oral BB use within the first 24 hours of ACS onset resulted in decreased in-hospital mortality.
To our knowledge, we are the first to report that BB on discharge from ACS have a short-term benefit that is lost only after 6 months. However, the neutral effect of BB on one-year mortality and beyond has been reported by several observational studies: In the French FAST-MI registry of ACS, BB did not reduce 1-year and 5-year mortality. Similar findings were reported in a sub-study of the British Myocardial Ischemia National Audit Project that assessed one-year mortality in ACS patients with a preserved LVEF. A 2015 meta-analysis of over 40,000 patients admitted for ACS found that the survival benefit of BB is lost beyond 1 year.

It is not known why BB protect only on the short-term. During acute MI, the sympathetic nervous system is activated and plasma catecholamines are elevated, which increases the risk of arrhythmogenesis. It is believed that BB counteract those deleterious pathophysiological effects, decrease the myocardial oxygen demand and reduce the infarct size, hence decreasing the risk of short-term mortality post-MI. In the current era, early reperfusion, dual anti-platelet therapy, statins use and other treatment have greatly contributed to the preservation of the myocardium and limited its damage post-ACS. It might be possible that chronic BB therapy, once

| Variable                      | Beta-blockers on discharge N = 1630 (84.9%) | No beta-blockers on discharge N = 291 (15.1%) | p     |
|-------------------------------|-------------------------------------------|-----------------------------------------------|-------|
| **Demographics**              |                                           |                                               |       |
| Age (years)                   | 59.3 ± 12.3                               | 60.8 ± 14.0                                   | 0.08  |
| Gender (Male)                 | 1109 (68.0%)                              | 151 (51.9%)                                   | <0.001|
| BMI (kg/m²)                   | 29.4 ± 8.0                                | 30.8 ± 9.6                                    | 0.21  |
| Smoking (current)             | 417 (25.6%)                               | 73 (25.1%)                                    | 0.85  |
| **Past medical history**      |                                           |                                               |       |
| Dyslipidemia                  | 886 (54.4%)                               | 160 (55.0%)                                   | 0.84  |
| Hypertension                  | 1039 (63.7%)                              | 193 (66.3%)                                   | 0.39  |
| Diabetes                      | 839 (51.5%)                               | 144 (49.5%)                                   | 0.53  |
| Myocardial infarction         | 317 (19.4%)                               | 50 (17.2%)                                    | 0.36  |
| Stroke/TIAs                   | 97 (6.0%)                                 | 19 (6.5%)                                     | 0.70  |
| PAD                           | 30 (1.8%)                                 | 9 (3.1%)                                      | 0.16  |
| Cancer                        | 24 (1.5%)                                 | 3 (1.0%)                                      | 0.78  |
| Venous thrombo-embolism       | 4 (0.2%)                                  | 1 (0.3%)                                      | 0.56  |
| CKD                           | 95 (5.8%)                                 | 14 (4.8%)                                     | 0.49  |
| **Clinical parameters**       |                                           |                                               |       |
| SBP, mmHg, mean ± SD          | 144.0 ± 26.8                              | 139.2 ± 27.5                                  | 0.005 |
| DBP, mmHg, mean ± SD          | 82.1 ± 15.4                               | 77.5 ± 15.3                                   | <0.001|
| HR, bpm, mean ± SD            | 83.9 ± 19.7                               | 81.8 ± 22.1                                   | 0.12  |
| LVEF, %                       | 53.2 ± 8.2                                | 52.8 ± 8.4                                    | 0.46  |
| **Medications at discharge**  |                                           |                                               |       |
| Aspirin                       | 1588 (97.4%)                              | 269 (92.4%)                                   | <0.001|
| ACE-inhibitors and/or ARBs    | 1380 (84.7%)                              | 199 (68.4%)                                   | <0.001|
| Statins                       | 1603 (98.3%)                              | 268 (92.1%)                                   | <0.001|
| Clopidogrel or prasugrel      | 1259 (77.2%)                              | 184 (63.2%)                                   | <0.001|
| **Discharge diagnosis**       |                                           |                                               |       |
| STEMI                         | 387 (26.7%)                               | 45 (17.2%)                                    | 0.001 |
| NSTEMI                        | 659 (45.4%)                               | 136 (52.1%)                                   | 0.046 |
| Unstable Angina               | 405 (27.9%)                               | 80 (30.7%)                                    | 0.36  |
| **Treatment**                 |                                           |                                               |       |
| PCI*                          | 452 (27.7%)                               | 65 (22.3%)                                    | 0.056 |
| Thrombolysis                  | 239 (14.7%)                               | 30 (10.3)                                     | 0.054 |
| CABG                          | 39 (2.4%)                                 | 5 (1.7%)                                      | 0.47  |
| **Severity of lesions**       |                                           |                                               |       |
| 1 artery                      | 73 (34.2%)                                | 74 (46.2%)                                    | 0.18  |
| 2 arteries                    | 69 (32.4%)                                | 35 (21.9%)                                    |       |
| 3 arteries                    | 64 (30%)                                  | 35 (21.9%)                                    |       |
| 4 arteries                    | 7 (3.3%)                                  | 4 (2.5%)                                      |       |

Table 2. Baseline characteristics of patients discharged alive from ACS in the GULF-COAST, with a LVEF >40%, according to beta-blockers on discharge. Data are shown as number (percentage) or mean ± standard deviation. TIAs = transient ischemic attacks, PAD = peripheral artery disease, CKD = chronic kidney disease, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, LVEF = Left ventricular ejection fraction, ARBs = angiotensin receptor blockers, STEMI = ST elevation myocardial infarction, NTSEMI = Non- ST-elevation myocardial infarction, PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft. * Including primary PCI. ** Among patients who underwent PCI.
reported that a previous BB therapy in patients hospitalized for acute HF is associated with decreased in-hospital meta-analysis with a low quality of evidence. We have recently shown that a previous beta-blocker therapy using beta-blockers in heart failure with preserved ejection fraction (HFpEF) in the presence of 2 inconclusive apoptosis and hypertrophy. However, it is not clear whether any cardiovascular protection could be achieved –receptor stimulation (arrhythmias, cardiomyocytes burden.

| Beta-blockers at discharge | Number of events (%) OR 95% CI | Number of events (%) OR 95% CI | Number of events (%) OR 95% CI | Number of events (%) OR 95% CI | Number of events (%) OR 95% CI |
|---------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| No                        | 7 (2.5%)                        | 8 (3.1%)                        | 9 (3.4%)                        | 2 (0.7%)                        | 2 (0.7%)                        |
|                           | OR = 1                          | OR = 1                          | OR = 1                          | OR = 1                          | OR = 1                          |
| Yes                       | 11 (0.7%)                       | 41 (2.7%)                       | 38 (2.5%)                       | 17 (1.0%)                       | 5 (0.3%)                        |
|                           | OR = 0.28 (0.11-0.73)           | OR = 0.86 (0.40-1.86)           | OR = 0.74 (0.35-1.55)           | OR = 1.52 (0.35-6.63)           | OR = 0.44 (0.02-2.30)           |
|                           | P value 0.008*                  | 0.71                            | 0.42                            | 0.57                            | 0.33                            |

Table 3. Medium-term outcomes of patients admitted for acute coronary syndrome at the GULF-COAST, with a LVEF >= 40%, according to beta-blockers on discharge.

recommended to prevent remodeling of the infarct zone in the pre-perfusion era, is not necessary anymore. In a recent study that assessed LV remodeling by repeating echocardiographic measurements 8 months post-MI, BB did not change any LV parameters in patients who had coronary revascularization and received secondary prevention medications.

Beta-blocker therapy has also been the cornerstone treatment of heart failure (HF) for the past 3 decades. Robust data from randomized controlled trials (RCTs) and metaanalysis support the use of BB in patients with heart failure and reduced ejection fraction (HFrEF) in chronic, and even in acute HF. We have already reported that a previous BB therapy in patients hospitalized for acute HF is associated with decreased in-hospital mortality. Additionally, we have shown that non-withdrawal of BB during acute decompensation is safe and is associated with better in-hospital outcome. It is believed that the protective effect of BB in HFrEF is secondary to their ability to reduce the deleterious effect of chronic β-receptor stimulation (arrhythmias, cardiomyocytes apoptosis and hypertrophy). However, it is not clear whether any cardiovascular protection could be achieved using beta-blockers in heart failure with preserved ejection fraction (HFpEF) in the presence of 2 inconclusive meta-analysis with a low quality of evidence. We have recently shown that a previous beta-blocker therapy had a neutral effect on in-hospital outcome in acute decompensated HFpEF patients with coronary artery disease, a similar outcome at one year was observed with the administration of beta-blockers at discharge from the hospital.

We acknowledge the presence of several limitations in our study. This was not a randomized controlled trial, rather an observational cohort of ACS. Important factors such as the type of BB, its dose and duration in patients already treated on BB on admission, were not recorded. Moreover, patients were not monitored for adherence after discharge, which could have influenced the long-term mortality. In our regression model and in our sensitivity analysis, we included several predictors of mortality. However, we cannot exclude the presence of other factors not recorded in our cohort that could have influenced the outcome. Finally, nearly two-thirds of the patients were not revascularized during their hospital stay; hence, these conclusions may only be relevant to non-revascularized ACS patients.

In summary, this study shows that BB therapy has a beneficial effect on mortality in ACS patients, with a LVEF >= 40% when used prior to, or within 24 hours of admission. BB therapy also improves mortality when given on discharge for up to one month. However, no further protective effect on mortality, reinfarction and stroke is observed beyond 6 months. Further studies are needed to clarify whether beta-blocker therapy post-ACS should not be given according to the left ventricular ejection fraction, but rather according to the remaining ischemia burden.

Methods
Study group. The Gulf COAST registry is a prospective, multicenter study of ACS patients recruited for 12 months (January 2012 to January 2013), from 4 Middle Eastern Gulf countries: Bahrain, Kuwait, Oman and United Arab Emirates. The study describes clinical characteristics and cardiovascular outcome of patients admitted with ACS. Details pertaining to the study design, methodology and recruitment have been previously published. Briefly, we consecutively enrolled Gulf Nationals from 29 hospitals, 18 years or older, admitted for ACS. Patients were then followed at 1, 6 and 12 months after discharge, at the clinic or by a telephone interview. All cardiovascular outcomes and clinical measurements were defined according to the American College of Cardiology (ACC)/American heart association (AHA) task force on clinical data standards. ACS included unstable angina (UA), non-ST segment myocardial infarction (NSTEMI) and ST segment myocardial infarction (STEMI). The study was approved and oversighted by the institutional ethics committee of Kuwait University (Number XX02/11), and subsequently by the local institutional ethics committees of each of the 29 participating hospitals. A written informed consent was obtained from every study participant. The study conformed to the 1975 Helsinki declaration and the STROBE epidemiological reporting guidelines.

In this study, we first assessed in-hospital mortality in ACS patients with a left ventricular ejection fraction (LVEF) >= 40%, in relation to BB on admission and at 24 hours post-admission. We then studied mortality in the same group of patients at 1-, 6- and 12-months in relation to BB on discharge. Additionally, reinfarction and stroke were assessed at 12 months.

Statistical analysis. Baseline categorical variables and outcome measures were summarized using frequency distributions while means and standard deviations were used for continuous variables. Outcome
measures and baseline patients’ characteristics were compared between the two groups: BB versus no BB using the χ² test (or Fisher’s exact test when expected cell counts fell below 5) for categorical variables and the student’s t test or Wilcoxon rank sum test for numeric variables as previously described. Multivariable logistic regression analysis was performed for mortality when the latter was statistically different in the study groups. The model included variables that were statistically significant between both groups, except for variables that have a high risk of co-linearity, in addition to age, gender. The model for in-hospital mortality included age, gender, smoking, dyslipidemia, hypertension, previous MI, heart rate, aspirin and diabetes. The model for one-month mortality included age, gender, systolic blood pressure (SBP), medications at discharge and discharge diagnosis. In order to test if the association between BB and mortality is different for those with vascularization vs. those without and for those with different types of ACS, interaction terms were included in the logistic regressions. Adjusted Odds Ratios (OR) are presented with their 95% CI and corresponding p values. Statistical significance was set at the 5% level (two-tailed test). All analyses were done using IBM-SPSS version 22.0.

**Sensitivity analysis.** We performed a propensity score analysis of participants on BB versus non-BB, on admission and on discharge. Propensity scores were computed using logistic regression with membership in the two groups on 6 baseline variables that are significantly different between the two study arms on admission: age, gender, smoking, dyslipidemia, hypertension, MI (prior to admission) and heart rate, using the 1:1 nearest neighbor matching method with a tolerance level of 0.01. Further multivariable logistic regression analysis was performed and included variables that were still significantly different after propensity matching: Aspirin, ACE-inhibitors/ARBs, statins and clopidogrel/prasugrel for in-hospital mortality in both models.

**Data availability**

The data that support the findings of this study are available from the authors upon reasonable request and with permission of the GULF-COAST principal investigator.

Received: 8 October 2019; Accepted: 12 February 2020; Published online: 26 February 2020

**References**

1. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2, 57–66 (1986).
2. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247, 1707–1714 (1982).
3. Yusuf, S., Peto, R., Lewis, J., Collins, R. & Sleight, P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis. 27, 335–371 (1985).
4. Bangalore, S. et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. Am. J. Med. 127, 939–953, https://doi.org/10.1016/j.amjmed.2014.05.032 (2014).
5. Chatterjee, S. et al. Early intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. Int. J. Cardiol. 168, 915–921, https://doi.org/10.1016/j.ijcard.2012.10.050 (2013).
6. Luscher, T. F. Acute coronary syndromes: mechanisms, reperfusion injury, antithrombotic therapy, and current outcomes. Eur. Heart J. 37, 1257–1259, https://doi.org/10.1093/eurheartj/ehw142 (2016).
7. Bugiardini, R. et al. Comparison of Early Versus Delayed Oral beta-Blockers in Acute Coronary Syndromes and Effect on Outcomes. Am. J. Cardiol. 117, 760–767, https://doi.org/10.1016/j.amjcard.2015.11.059 (2016).
8. Ibáñez, B. et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 128, 1495–1503, https://doi.org/10.1161/CIRCULATIONAHA.113.006533 (2013).
9. de Matos Soeiro, A. et al. Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome. Clin. Cardiol. 40, 353–358, https://doi.org/10.1002/clc2.13013 (2017).
10. Puyimurat, E. et al. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 354, i4801, https://doi.org/10.1136/bmj.i4801 (2016).
11. Dondo, T. R. et al. Beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J. Am. Coll. Cardiol. 69, 2710–2720, https://doi.org/10.1016/j.jacc.2017.03.578 (2017).
12. Huang, B. T. et al. Meta-Analysis of Relation Between Oral beta-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Am. J. Cardiol. 115, 1529–1538, https://doi.org/10.1016/j.amjcard.2015.02.057 (2015).
13. Jardine, D. L. et al. Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model. J. Physiol. 565, 325–333, https://doi.org/10.1113/jphysiol.2004.082198 (2005).
14. Little, R. A. et al. Plasma catecholamines in the acute phase of the response to myocardial infarction. Arch. Emerg. Med. 3, 20–27 (1986).
15. Kolettis, T. M. et al. Central Sympathetic Activation and Arrhythmogenesis during Acute Myocardial Infarction: Modulating Effects of Eotaxin-1 & Receptors. Front. Cardiovasc. Med. 2, 6, https://doi.org/10.3389/fcvm.2015.00006 (2015).
16. Iwasaki, K., Kusachi, S., Kita, T., Taniguchi, G. & Tsuji, T. Effects of reperfusion on left ventricular ejection fraction and volume after acute myocardial infarction. Jpn. J. Physiol. 56, 783–792 (1992).
17. Gallone, G. et al. Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 72, 2886–2903, https://doi.org/10.1016/j.jacc.2018.09.052 (2018).
18. Horisuchi, Y. et al. Effects of beta-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. Int. J. Cardiol. 221, 765–769, https://doi.org/10.1016/j.ijcard.2016.07.123 (2016).
19. Braunwald, E. The war against heart failure: the Lancet lecture. Lancet 385, 812–824, https://doi.org/10.1016/S0140-6736(14)61889-4 (2015).
20. Prins, K. W., Neill, J. M., Tyler, J. O., Eckman, P. M. & Duval, S. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 3, 647–653, https://doi.org/10.1016/j.jchf.2015.03.008 (2015).
21. Fukuta, H., Goto, T., Wakami, K. & Ohte, N. The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies. Int. J. Cardiol. 228, 4–10, https://doi.org/10.1016/j.ijcard.2016.11.239 (2017).
22. Abi Khalil, C. et al. Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013). Curr. Vasc. Pharmacol. 15, 77–83 (2017).
23. Abi Khalil, C. et al. Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East. BMJ Open. 7, e014915, https://doi.org/10.1136/bmjopen-2016-014915 (2017).

24. Lohse, M. J., Engelhardt, S. & Eschenhagen, T. What is the role of beta-adrenergic signaling in heart failure? Circ. Res. 93, 896–906, https://doi.org/10.1161/01.RES.0000102042.83024.CA (2003).

25. Martin, N., Manoharan, K., Thomas, J., Davies, C. & Lumbers, R. T. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst. Rev. 6, CD012721, https://doi.org/10.1002/14651858.CD012721.pub2 (2018).

26. Abi Khalil, C. et al. Beta-blockers and cardiovascular outcomes in acute heart failure with a history of coronary artery disease and an ejection fraction > 40%. Curr Vasc Pharmacol, https://doi.org/10.2174/1570161118666191231114203 (2019).

27. Zubaid, M. et al. Design and Rationale of Gulf locals with Acute Coronary Syndrome Events (Gulf Coast) Registry. Open. Cardiovasc. Med. J. 8, 88–93, https://doi.org/10.2174/1874192401408010088 (2014).

28. Weintraub, W. S. et al. ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. J. Am. Coll. Cardiol. 58, 202–222, https://doi.org/10.1016/j.jacc.2011.05.001 (2011).

29. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull. World Health Organ. 85, 867–872, https://doi.org/10.2471/blt.07.045120 (2007).

30. Abi Khalil, C. et al. beta-Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In-Hospital and 12-Month Outcome: Results From the GULF-RACE 2 (Gulf Registry of Acute Coronary Events-2). J Am Heart Assoc 6, https://doi.org/10.1161/JAHA.117.007631 (2017).

Acknowledgements
Gulf COAST is an investigator-initiated study, financially supported by AstraZeneca and sponsored and overseen by Kuwait University. Dr Abi Khalil’s lab is funded by a grant from the Qatar National Research Funds under its National Priorities Research Program award number NPRP10-0207-170385. All of the above-mentioned sources did not have a role in the study’s concept, analysis and writing of the manuscript.

Author contributions
C.A.K. conceived and designed the analysis. M.Z. collected clinical data. Z.M. performed statistical analysis. C.A.K., N.A. and J.A.S. analyzed the data. M.M. wrote the manuscript and prepared figures. All authors critically reviewed and subsequently approved the final version.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-60528-y.

Correspondence and requests for materials should be addressed to C.A.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020